-
Scioto Biosciences, Inc. Announces Top-Line Results of SB-121 in a Phase Ib Trial in Patients Diagnosed With Autism Spectrum Disorder
-
Scioto Biosciences, Inc. Announces First Patient Dosed in Phase Ib Study in Patients Diagnosed with Autistic Disorder
-
Scioto Biosciences Receives Series B Investment from Genome & Company
Activated Bacterial Therapeutic Platform
Optimizing Microbiome Delivery
ABT Platform Phase 1 ResultsAdvancing Healing Through Microbiome Therapeutics
Scioto Biosciences is a clinical stage biotech company dedicated to innovative research and discovery in the field of microbiome therapeutics. Our team has developed a proprietary Activated Bacterial Therapeutics (ABT) platform for delivering best-in-class, live therapeutic bacteria to the gut. Our solution is focused on the activation of beneficial bacteria that have the potential to advance healing for various diseases associated with the GI tract, Oncology and CNS indications.
About Us